2 - 4 October | Copenhagen, Denmark
ISSCR iPSC-derived cell therapies
Pluripotent stem cell-derived cell therapies are accelerating rapidly into clinical trials. The ISSCR, in partnership with Novo Nordisk, will gather pioneers at the forefront of ESC and iPSC-derived cell therapies-renowned scientists and innovators will share the latest updates on ongoing clinical trials, as well as groundbreaking platforms and technologies that will revolutionise the next generation of cell therapies
Pluripotent stem cell-derived cell therapies are accelerating rapidly into clinical trials. The ISSCR, in partnership with Novo Nordisk, will gather pioneers at the forefront of ESC and iPSC-derived cell therapies-renowned scientists and innovators will share the latest updates on ongoing clinical trials, as well as groundbreaking platforms and technologies that will revolutionise the next generation of cell therapies
We are sponsoring this event!
We are delighted to sponsor this event. The biggest hurdle in cell therapy today is access to consistent batches of human cell types at scale. Therapeutic development needs trillions of cells at an affordable cost in order to generate medicines that are accessible to millions of patients. bit.bio’s cell coding platform is able to provide a source of defined human cell types that are inherently consistent and scalable. We believe that our approach also has the potential to reduce the cost of cell therapies by up to two orders of magnitude
We have the ability to create any human cell type and manufacture it with consistency at scale. This unlocks unparalleled opportunities in cell therapy.
Arrange a meeting